Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Bayer and Crispr Therapeutics teamed up in December 2015 to launch Casebia Therapeutics to develop gene-editing therapies for blood, eye, and heart diseases. Bayer pledged $300 million to the start-up, and Crispr pitched in $35 million. Bayer now plans to give Crispr full control of Casebia, although it still has rights to opt into two of the firm’s programs. Casebia is developing gene-editing therapies for hemophilia, multiple genetic forms of blindness, and a rare autoimmune disorder.
This article has been sent to the following recipient: